Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 07, 2019

SELL
$15.58 - $28.41 $1,246 - $2,272
-80 Closed
0 $0
Q3 2018

Nov 01, 2018

BUY
$25.99 - $30.6 $2,079 - $2,448
80 New
80 $2,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $88.3M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Jnba Financial Advisors Portfolio

Follow Jnba Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jnba Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Jnba Financial Advisors with notifications on news.